Milton C. Ault III - 12 Jul 2021 Form 4/A - Amendment Insider Report for Alzamend Neuro, Inc. (ALZN)

Role
10%+ Owner
Signature
/s/ Milton C. Ault, III
Issuer symbol
ALZN
Transactions as of
12 Jul 2021
Net transactions value
+$89,136
Form type
4/A - Amendment
Filing time
15 Jul 2021, 21:44:05 UTC
Date Of Original Report
14 Jul 2021
Previous filing
08 Jul 2021
Next filing
16 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALZN Common Stock Purchase $49,812 +8,100 +0.15% $6.15* 5,314,155 12 Jul 2021 By Digital Power Lending, LLC F1, F2
transaction ALZN Common Stock Purchase $5,637 +900 +0.02% $6.26* 5,315,055 13 Jul 2021 By Digital Power Lending, LLC F2, F3
transaction ALZN Common Stock Purchase $33,687 +5,500 +0.1% $6.12* 5,320,555 14 Jul 2021 By Digital Power Lending, LLC F2, F4, F5, F6
holding ALZN Common Stock 15,000,000 12 Jul 2021 By Ault Life Sciences, Inc. F7
holding ALZN Common Stock 10,000,000 12 Jul 2021 By Ault Life Sciences, Inc. F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $6.1496. The range of purchase prices on the transaction date was $5.92 to $6.22 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F2 Digital Power Lending, LLC ("DPL") is a wholly-owned subsidiary of Ault Global Holdings, Inc. ("AGH"). Mr. Ault, the Executive Chairman of AGH, is deemed to have voting and investment power with respect to the securities held of record by DPL.
F3 The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $6.2633. The range of purchase prices on the transaction date was $6.19 to $6.32 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F4 The original Form 4 filed on July 14, 2021, is amended by this Form 4 amendment to correct an error in the amount of shares from "5,000" to "5,500".
F5 The original Form 4 filed on July 14, 2021, is amended by this Form 4 amendment to correct an error in the Price from "$6.7374" to "6.1249". The common stock was purchased by the reporting person in open market transactions on the transaction date, with a volume weighted average purchase price of $6.1249. The range of purchase prices on the transaction date was $5.86 to $6.75 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.
F6 The original Form 4 filed on July 14, 2021, is amended by this Form 4 amendment to correct an error in the amount of shares from "5,320,055" to "5,320,555".
F7 Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
F8 Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.